United Therapeutics (UTHR) Deferred Taxes (2009 - 2026)

United Therapeutics (UTHR) posted Deferred Taxes of $25.9 million for Q1 2026, down 14.75% sequentially from $30.4 million in Q3 2012.

United Therapeutics (UTHR) Deferred Taxes (2009 - 2026) Analysis & Trends

United Therapeutics has reported Deferred Taxes for 5 years, with the latest figure at $25.9 million in Q1 2026.

Quarterly Deferred Taxes changed N/A year-over-year to $25.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $87.3 million (down 7.7% YoY) and the FY2025 annual result came in at $97.7 million, up 252.42% from the prior year.
Deferred Taxes retreated to $25.9 million in Q1 2026 per UTHR's latest filing, from $30.4 million in the prior quarter.
Over five years, Deferred Taxes peaked at $25.9 million in Q1 2026 and troughed at $25.9 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Haleon	44.07 Bn	43.10 Bn	-	-
2	Teva Pharmaceutical Industries	43.42 Bn	39.76 Bn	2.15 Bn	25.00 Mn
3	Zoetis	31.86 Bn	30.18 Bn	1.05 Bn	-33.00 Mn
4	Takeda Pharmaceutical	28.77 Bn	22.98 Bn	5.10 Bn	-
5	United Therapeutics	22.29 Bn	19.63 Bn	683.80 Mn	25.70 Mn
6	Viatris	18.78 Bn	17.89 Bn	1.46 Bn	-124.50 Mn
7	Neurocrine Biosciences	15.66 Bn	15.27 Bn	935.80 Mn	-25.30 Mn
8	Elanco Animal Health	11.91 Bn	11.38 Bn	798.00 Mn	-
9	Dr Reddys Laboratories	10.16 Bn	10.00 Bn	-	-
10	Alkermes	8.20 Bn	7.55 Bn	397.90 Mn	9.10 Mn

Download Data